How Long Do Semaglutide Side Effects Last?

If you are wondering how long do semaglutide side effects last, the short, evidence-based answer is that the common ones – nausea, vomiting, diarrhea, and constipation – are usually mild-to-moderate, non-serious, and transient, easing over days to weeks rather than persisting indefinitely. They tend to show up early in treatment and again after each dose increase, then settle as the body adapts. Individual experience varies, and a licensed provider directs every dosing and management decision. Below, we walk through the verified timeline, the numbers behind it, and the rarer warning signs that warrant prompt medical attention.

Why do semaglutide side effects happen at all?

Semaglutide is a GLP-1 receptor agonist. Among other effects, it slows how quickly the stomach empties, which is part of why GI symptoms like nausea and fullness are the most common reactions. Because the body needs time to adjust, FDA-approved semaglutide products are started low and increased gradually.

According to the FDA Wegovy (semaglutide) label on DailyMed, the dose is escalated about every 4 weeks – 0.25, then 0.5, then 1.0, then 1.7, and finally the 2.4 mg maintenance dose – and the label states this schedule exists “to minimize gastrointestinal adverse reactions.” The label also notes that these reactions increased during dose escalation. For type 2 diabetes, the Ozempic (semaglutide) label uses a different schedule: a 0.25 mg initiation dose that is not effective for glycemic control, then 0.5 mg, up to 1 mg, and a maximum of 2 mg once weekly.

How common are the side effects, and how severe?

Common does not mean severe. In the pooled adult chronic-weight-management trials reported in the Wegovy label (semaglutide 2.4 mg vs placebo), any GI disorder occurred in 73% of people on semaglutide versus 47% on placebo, while severe GI reactions were uncommon at 4.1% versus 0.9%. The specific reaction rates from that adult population are below.

Reaction (Wegovy 2.4 mg, adults)	Semaglutide	Placebo
Nausea	44%	16%
Diarrhea	30%	16%
Constipation	24%	11%
Vomiting	24%	6%
Abdominal pain	20%	10%

These rates come from the FDA Wegovy label adult population on semaglutide 2.4 mg and should not be blended with the diabetes-population (Ozempic) figures, which are different. They tell you how often effects occur – the duration question is answered separately, below.

How long do semaglutide side effects last, episode by episode?

The best primary source for duration is a pre-specified pooled analysis of STEP 1-3 participants on semaglutide 2.4 mg published by Wharton and colleagues in Diabetes, Obesity and Metabolism (2022). In that analysis, 99.5% of GI adverse events were non-serious and 98.1% were mild-to-moderate. Events were transient and clustered during and shortly after dose escalation, with the cumulative incidence of a first GI event plateauing after about week 20 – roughly four weeks after reaching the 2.4 mg maintenance dose.

For per-episode duration, a clinical review on PMC (Chao et al.) reports the median durations from that pooled STEP 1-3 dataset:

Symptom (pooled STEP 1-3, semaglutide 2.4 mg)	Median per-episode duration
Vomiting	~2 days
Diarrhea	~3 days
Nausea	~8 days
Constipation	~47 days

The pattern is clear: nausea, vomiting, and diarrhea episodes tend to resolve over a few days to roughly a week, while constipation tends to linger longest. “Median” means half of episodes were shorter and half longer, so your experience may differ. These are averages from a trial population, not a promise about any one person.

Do most people stop semaglutide because of side effects?

No – most do not. In the STEP 1 trial, reported in the New England Journal of Medicine, nausea and diarrhea were the most common adverse events; the authors describe them as typically transient and mild-to-moderate in severity, subsiding with time. GI-related discontinuation occurred in 4.5% of the semaglutide group versus 0.8% of placebo – meaning the large majority continued treatment and adjusted over time.

This mirrors the broader GLP-1 experience. If you are weighing semaglutide against another option, our overview of tirzepatide vs semaglutide and our guide to tirzepatide side effects walk through how a related medication compares. (Tirzepatide is a different drug; its trial figures should never be read as semaglutide results.)

What can help with the common GI effects?

General, non-personalized wellness strategies summarized in the clinical review on PMC include reducing high-fat, greasy, and fried foods, eating smaller portions, eating slowly, stopping when full, and avoiding eating late at night. Staying hydrated matters when nausea, vomiting, or diarrhea are present, and adequate fluids and fiber are commonly suggested for constipation.

The same review notes that prescriber-directed approaches – such as delaying an up-titration step or maintaining a lower tolerated dose – are decisions made by your clinician, not something to self-manage. Do not start, stop, slow, or change your dose on your own; follow the product’s Instructions for Use and your prescriber’s and pharmacist’s guidance. If you are also curious about onset, our companion piece on how long semaglutide takes to work covers the timeline from the other direction.

Which symptoms are rare but warrant prompt medical attention?

Beyond the common GI effects, the Wegovy label describes serious-but-rare risks. Contact a licensed healthcare provider or seek care promptly if you experience any of the following, drawn from the label’s Warnings and Precautions and Postmarketing Experience:

• Possible pancreatitis: severe, persistent abdominal pain, sometimes radiating to the back, with or without vomiting.
• Possible gallbladder problems: upper-right abdominal pain, fever, jaundice, or clay-colored stools.
• Dehydration / acute kidney injury: a majority of reported acute kidney injury events occurred after nausea, vomiting, or diarrhea caused volume depletion; watch for decreased urination or signs of dehydration.
• Possible ileus or intestinal obstruction: severe constipation or no bowel movement with bloating and vomiting (reported postmarketing).
• Low blood sugar (hypoglycemia): especially if you also take insulin or a sulfonylurea.
• Vision changes: diabetic retinopathy complications.
• Allergic reactions, increased heart rate, and any new or worsening depression, mood changes, or suicidal thoughts.

The Wegovy label also carries a boxed warning for thyroid C-cell tumors: in rodents, semaglutide caused dose- and duration-dependent thyroid C-cell tumors. It is unknown whether semaglutide causes such tumors, including medullary thyroid carcinoma (MTC), in humans – this is a rodent finding whose human relevance is undetermined – and it is contraindicated in people with a personal or family history of MTC or MEN 2. This material is educational and does not replace the full label or your provider’s judgment.

A note on FDA-approved versus compounded semaglutide

Wegovy and Ozempic (semaglutide) are FDA-approved. Compounded semaglutide is not FDA-approved and is not reviewed by the FDA for safety, effectiveness, or quality before marketing; per the FDA’s concerns about unapproved GLP-1 drugs, the agency has received adverse-event reports, including dosing errors with compounded products. It is also worth noting the supply context: the FDA determined the semaglutide shortage resolved by Declaratory Order on February 21, 2025 (tirzepatide was removed from the shortage list in October 2024 and re-affirmed resolved December 19, 2024), so the basis for mass compounding has ended. Discuss any GLP-1 product with a licensed provider.

How do side effects fit into the bigger picture?

It helps to keep efficacy and tolerability in perspective. In STEP 1, the mean body-weight change from baseline to week 68 was -14.9% with semaglutide 2.4 mg versus -2.4% with placebo, per the ACC trial summary; all participants received a reduced-calorie diet and increased physical activity. That figure is a trial average with wide individual variation – individual results vary – and is included here only for context, since this is a side-effect article. If weight management is your focus, our piece on peptides for weight loss offers broader background.

Frequently asked questions

How long does nausea from semaglutide usually last?

In the pooled STEP 1-3 analysis of semaglutide 2.4 mg, the median nausea episode lasted about 8 days, and most GI events were mild-to-moderate and transient. Nausea often appears early and after dose increases, then tends to ease. Your experience may differ; a provider directs management.

Why does constipation seem to last longer than nausea?

In that same pooled analysis, the median constipation episode was about 47 days – far longer than nausea (about 8 days), diarrhea (about 3 days), or vomiting (about 2 days). Constipation tends to linger longest among the common effects. General strategies such as adequate fluids and fiber are sometimes suggested, but persistent or severe constipation should be discussed with a provider.

Do semaglutide side effects come back after a dose increase?

They can. The FDA Wegovy label notes that GI reactions increased during dose escalation, and the pooled STEP 1-3 analysis found events clustered during and shortly after each roughly 4-week dose step, with first-event cumulative incidence plateauing after about week 20. The gradual schedule exists to minimize these reactions and is set by the label and your prescriber.

When should I contact a provider about side effects?

Seek care for severe or persistent abdominal pain, signs of gallbladder problems (upper-right pain, fever, jaundice, clay-colored stools), dehydration or decreased urination, severe constipation with bloating and vomiting, low-blood-sugar symptoms, vision changes, allergic reactions, or any new or worsening mood changes or suicidal thoughts. These are drawn from the Wegovy label and warrant prompt attention.

Is compounded semaglutide the same as Wegovy or Ozempic?

No. Wegovy and Ozempic (semaglutide) are FDA-approved. Compounded semaglutide is not FDA-approved and has not been evaluated by the FDA for safety, effectiveness, or quality. Always discuss any GLP-1 medication, approved or compounded, with a licensed provider.

Will I definitely get side effects on semaglutide?

Not necessarily. Side effects are common but not universal, and in STEP 1 only 4.5% of semaglutide participants discontinued for GI reasons versus 0.8% on placebo – meaning most people continued and adjusted over time. How you respond is individual, and eligibility and management are determined by a licensed provider.